Boron neutron capture therapy for newly diagnosed glioblastoma

Shinji Kawabata, Shin Ichi Miyatake, Toshihiko Kuroiwa, Kunio Yokoyama, Atsushi Doi, Kyoko Iida, Shiro Miyata, Naosuke Nonoguchi, Hiroyuki Michiue, Masatsugu Takahashi, Taisuke Inomata, Yoshio Imahori, Mitsunori Kirihata, Yoshinori Sakurai, Akira Maruhashi, Hiroaki Kumada, Koji Ono

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT (protocol 1), and the last 11 were treated with BNCT followed by XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT (protocol 1 plus 2) showed a significant survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in correspondence with the RTOG- and EORTC-RPA subclasses. The median survival time (MST) was 15.6 months for protocols 1 and 2 together. For protocol 2, the MST was 23.5 months. The main causes of death were cerebrospinal fluid dissemination as well as local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.

Original languageEnglish
Pages (from-to)51-60
Number of pages10
JournalJournal of Radiation Research
Volume50
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Boron Neutron Capture Therapy
Glioblastoma
therapy
boron
neutrons
tumors
prognosis
Survival
X-Rays
cerebrospinal fluid
Recurrence
prolongation
Neoplasms
chemotherapy
death
progressions
Cerebrospinal Fluid
Cause of Death
x rays
sodium

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Health, Toxicology and Mutagenesis

Cite this

Kawabata, S., Miyatake, S. I., Kuroiwa, T., Yokoyama, K., Doi, A., Iida, K., ... Ono, K. (2009). Boron neutron capture therapy for newly diagnosed glioblastoma. Journal of Radiation Research, 50(1), 51-60. https://doi.org/10.1269/jrr.08043

Boron neutron capture therapy for newly diagnosed glioblastoma. / Kawabata, Shinji; Miyatake, Shin Ichi; Kuroiwa, Toshihiko; Yokoyama, Kunio; Doi, Atsushi; Iida, Kyoko; Miyata, Shiro; Nonoguchi, Naosuke; Michiue, Hiroyuki; Takahashi, Masatsugu; Inomata, Taisuke; Imahori, Yoshio; Kirihata, Mitsunori; Sakurai, Yoshinori; Maruhashi, Akira; Kumada, Hiroaki; Ono, Koji.

In: Journal of Radiation Research, Vol. 50, No. 1, 2009, p. 51-60.

Research output: Contribution to journalArticle

Kawabata, S, Miyatake, SI, Kuroiwa, T, Yokoyama, K, Doi, A, Iida, K, Miyata, S, Nonoguchi, N, Michiue, H, Takahashi, M, Inomata, T, Imahori, Y, Kirihata, M, Sakurai, Y, Maruhashi, A, Kumada, H & Ono, K 2009, 'Boron neutron capture therapy for newly diagnosed glioblastoma', Journal of Radiation Research, vol. 50, no. 1, pp. 51-60. https://doi.org/10.1269/jrr.08043
Kawabata S, Miyatake SI, Kuroiwa T, Yokoyama K, Doi A, Iida K et al. Boron neutron capture therapy for newly diagnosed glioblastoma. Journal of Radiation Research. 2009;50(1):51-60. https://doi.org/10.1269/jrr.08043
Kawabata, Shinji ; Miyatake, Shin Ichi ; Kuroiwa, Toshihiko ; Yokoyama, Kunio ; Doi, Atsushi ; Iida, Kyoko ; Miyata, Shiro ; Nonoguchi, Naosuke ; Michiue, Hiroyuki ; Takahashi, Masatsugu ; Inomata, Taisuke ; Imahori, Yoshio ; Kirihata, Mitsunori ; Sakurai, Yoshinori ; Maruhashi, Akira ; Kumada, Hiroaki ; Ono, Koji. / Boron neutron capture therapy for newly diagnosed glioblastoma. In: Journal of Radiation Research. 2009 ; Vol. 50, No. 1. pp. 51-60.
@article{7ba027044b424e1699824aa531711a84,
title = "Boron neutron capture therapy for newly diagnosed glioblastoma",
abstract = "We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT (protocol 1), and the last 11 were treated with BNCT followed by XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT (protocol 1 plus 2) showed a significant survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in correspondence with the RTOG- and EORTC-RPA subclasses. The median survival time (MST) was 15.6 months for protocols 1 and 2 together. For protocol 2, the MST was 23.5 months. The main causes of death were cerebrospinal fluid dissemination as well as local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.",
author = "Shinji Kawabata and Miyatake, {Shin Ichi} and Toshihiko Kuroiwa and Kunio Yokoyama and Atsushi Doi and Kyoko Iida and Shiro Miyata and Naosuke Nonoguchi and Hiroyuki Michiue and Masatsugu Takahashi and Taisuke Inomata and Yoshio Imahori and Mitsunori Kirihata and Yoshinori Sakurai and Akira Maruhashi and Hiroaki Kumada and Koji Ono",
year = "2009",
doi = "10.1269/jrr.08043",
language = "English",
volume = "50",
pages = "51--60",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "1",

}

TY - JOUR

T1 - Boron neutron capture therapy for newly diagnosed glioblastoma

AU - Kawabata, Shinji

AU - Miyatake, Shin Ichi

AU - Kuroiwa, Toshihiko

AU - Yokoyama, Kunio

AU - Doi, Atsushi

AU - Iida, Kyoko

AU - Miyata, Shiro

AU - Nonoguchi, Naosuke

AU - Michiue, Hiroyuki

AU - Takahashi, Masatsugu

AU - Inomata, Taisuke

AU - Imahori, Yoshio

AU - Kirihata, Mitsunori

AU - Sakurai, Yoshinori

AU - Maruhashi, Akira

AU - Kumada, Hiroaki

AU - Ono, Koji

PY - 2009

Y1 - 2009

N2 - We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT (protocol 1), and the last 11 were treated with BNCT followed by XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT (protocol 1 plus 2) showed a significant survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in correspondence with the RTOG- and EORTC-RPA subclasses. The median survival time (MST) was 15.6 months for protocols 1 and 2 together. For protocol 2, the MST was 23.5 months. The main causes of death were cerebrospinal fluid dissemination as well as local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.

AB - We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT (protocol 1), and the last 11 were treated with BNCT followed by XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT (protocol 1 plus 2) showed a significant survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in correspondence with the RTOG- and EORTC-RPA subclasses. The median survival time (MST) was 15.6 months for protocols 1 and 2 together. For protocol 2, the MST was 23.5 months. The main causes of death were cerebrospinal fluid dissemination as well as local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.

UR - http://www.scopus.com/inward/record.url?scp=62549142671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549142671&partnerID=8YFLogxK

U2 - 10.1269/jrr.08043

DO - 10.1269/jrr.08043

M3 - Article

C2 - 18957828

AN - SCOPUS:62549142671

VL - 50

SP - 51

EP - 60

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 1

ER -